India’s patent office decided to reject pharma giant Johnson &Johnson’s appeal to extend the patent for a life-saving TB medicine called bedaquiline which is used to treat those with drug resistant infections. But for a long time before this, Johnson & Johnson was enjoying a monopoly in India. Generic manufacturers could not make this life-saving medicine. The Indian government too, at the time, had decided to protect the pharma giant.Not just that, Johnson & Johnson was also conveniently projecting itself as a charitable organisation through its health programmes.What does the Indian govt’s decision mean for TB patients in India now?
Join The Ken as a Podcast Producer and work with India's most ambitious storytellers! We’re creating a podcast about India’s biggest companies, with each episode backed by weeks of deep research. You’ll lead the workflows that turn that research into exceptional narratives and bring the show to listeners around the world. Join us to help shape something exceptional. Check out the details and apply here. 

Ver todos los episodios